Page 116 - Read Online

Procaccianti et al. Microbiome Res Rep 2023;2:24 https://dx.doi.org/10.20517/mrr.2023.23 Page 11 of 12

54. Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients
treated with ipilimumab. Ann Oncol 2017;28:1368-79. DOI PubMed
55. Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated braf wild-type advanced melanoma
treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol 2019;5:187-94. DOI PubMed PMC
56. Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (checkmate
017 and checkmate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 2018;29:959-65. DOI
57. Escudier B, Motzer RJ, Sharma P, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with
nivolumab in checkmate 025. Eur Urol 2017;72:368-76. DOI
58. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced
melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30. DOI PubMed PMC
59. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after
anti-CTLA-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84. DOI
60. Derosa L, Routy B, Thomas AM, et al. Intestinal akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with
advanced non-small-cell lung cancer. Nat Med 2022;28:315-24. DOI PubMed PMC
61. Gupta KH, Nowicki C, Giurini EF, Marzo AL, Zloza A. Bacterial-based cancer therapy (BBCT): recent advances, current challenges,
and future prospects for cancer immunotherapy. Vaccines 2021;9:1497. DOI PubMed PMC
62. Tang Q, Peng X, Xu B, Zhou X, Chen J, Cheng L. Current status and future directions of bacteria-based immunotherapy. Front
Immunol 2022;13:911783. DOI PubMed PMC
63. Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut 2020;69:1867-76. DOI PubMed PMC
64. Longhi G, van Sinderen D, Ventura M, Turroni F. Microbiota and cancer: the emerging beneficial role of bifidobacteria in cancer
immunotherapy. Front Microbiol 2020;11:575072. DOI PubMed PMC
65. Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-pd-l1 efficacy.
Science 2015;350:1084-9. DOI PubMed PMC
+
66. Rong Y, Dong Z, Hong Z, et al. Reactivity toward bifidobacterium longum and enterococcus hirae demonstrate robust CD8 t cell
response and better prognosis in hbv-related hepatocellular carcinoma. Exp Cell Res 2017;358:352-9. DOI PubMed
67. Luu M, Riester Z, Baldrich A, et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive
immunotherapy for cancer. Nat Commun 2021;12:4077. DOI PubMed PMC
68. Li X, Fu GF, Fan YR, et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor
of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003;10:105-11. DOI
69. Cronin M, Akin AR, Collins SA, et al. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting.
PLoS One 2012;7:e30940. DOI PubMed PMC
70. D'Amico F, Perrone AM, Rampelli S, et al. Gut microbiota dynamics during chemotherapy in epithelial ovarian cancer patients are
related to therapeutic outcome. Cancers 2021;13:3999. DOI PubMed PMC
71. San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation
of the warburg effect. Carcinogenesis 2017;38:119-33. DOI PubMed PMC
72. la Cruz-López KG, Castro-Muñoz LJ, Reyes-Hernández DO, García-Carrancá A, Manzo-Merino J. Lactate in the regulation of tumor
microenvironment and therapeutic approaches. Front Oncol 2019;9:1143. DOI PubMed PMC
73. Vinasco K, Mitchell HM, Kaakoush NO, Castaño-Rodríguez N. Microbial carcinogenesis: lactic acid bacteria in gastric cancer.
Biochim Biophys Acta Rev Cancer 2019;1872:188309. DOI PubMed
74. Fidelle M, Rauber C, Alves Costa Silva C, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into
cancers. Science 2023;380:eabo2296. DOI
75. Sarkar T, Dhar S, Sa G. Tumor-infiltrating t-regulatory cells adapt to altered metabolism to promote tumor-immune escape. Curr Res
Immunol 2021;2:132-41. DOI PubMed PMC
76. Hidalgo-Cantabrana C, Delgado S, Ruiz L, Ruas-Madiedo P, Sánchez B, Margolles A. Bifidobacteria and their health-promoting
effects. Microbiol Spectr 2017:5. DOI PubMed
77. Leu RK, Hu Y, Brown IL, Woodman RJ, Young GP. Synbiotic intervention of bifidobacterium lactis and resistant starch protects
against colorectal cancer development in rats. Carcinogenesis 2010;31:246-51. DOI PubMed
78. Roller M, Clune Y, Collins K, Rechkemmer G, Watzl B. Consumption of prebiotic inulin enriched with oligofructose in combination
with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in
polypectomised and colon cancer patients. Br J Nutr 2007;97:676-84. DOI PubMed
79. Liu Z, Li C, Huang M, et al. Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after
colorectal liver metastases surgery: a double-center and double-blind randomized clinical trial. BMC Gastroenterol 2015;15:34. DOI
PubMed PMC
80. Liu ZH, Huang MJ, Zhang XW, et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent
postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am J
Clin Nutr 2013;97:117-26. DOI PubMed
81. Wada M, Nagata S, Saito M, et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy
for pediatric malignancies. Support Care Cancer 2010;18:751-9. DOI
82. Lages PC, Generoso SV, Correia MITD. Postoperative symbiotic in patients with head and neck cancer: a double-blind randomised